-
2023-504912-13-00
4
2025-01-09
Prostate Cancer
-
2023-508418-40-00
9
2024-12-16
Head and Neck Squamous Cell Carcinoma
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2023-504910-31-00
5
2024-07-15
Non-small Cell Lung Cancer (NSCLC)
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2022-501697-19-01
5
2024-06-18
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
-
2023-504145-31-00
4
2024-06-10
HER2 negative breast cancer
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-506308-24-00
10
2024-05-22
Recurrent or metastatic head and neck squamous cell carcinoma
-
2024-517804-12-00
5
2024-04-17
Heart failure – post-anthracycline cardiomyopathy
-
2023-504374-38-00
5
2024-04-12
Locally advanced cervical cancer
-
2023-503208-94-00
6
2024-04-04
Prostate cancer
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2024-515064-31-00
4
2022-12-01
Refractory / relapsed Hodgkin's lymphoma
-
2024-517535-52-00
6
2022-08-24
Glioblastoma Multiforme
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-517480-23-00
4
2022-02-17
Head and neck squamous cell carcinoma
-
2024-517479-19-00
4
2021-08-26
Nasopharyngeal Cancer
-
2024-515063-66-00
4
2021-03-30
Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease